CS
CSPC Pharmaceutical Group Limited
CSPCY · OTC
$4.74 +0.42% (+$0.02)
1M -5.22%
Market Cap ¥90.9B
P/E Ratio 24.09x
Div. Yield 3.15%
ROE 11.08%
Bulios Fair Price
$3.51
25.9% downside
Current Price
$4.74
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CSPCY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
49 /100
Fair P/E 24.09x
EV/EBITDA 16.34x
P/S 3.60x
Growth
4 /100
Declining EPS growth 13.51%
Rev. growth 6.50%
FCF growth 10.20%
Profitability
82 /100
Strong Gross margin 65.59%
Net margin 14.93%
Op. margin 15.27%
Quality
52 /100
Average ROIC 8.42%
ROE 11.08%
ROA 8.08%
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 2.19x
Int. coverage 102.89x
Stability
91 /100
Stable Beta 0.75x
Rev. volatility 15.30%
EPS volatility 12.16%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CSPCY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Lei Cai
Employees
19,700
Headquarters
Shijiazhuang
Upcoming events
21 OCT
Ex-Dividend
Ex-dividend date
25 NOV
Dividend Payment
Payment date